Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-25-280166
Filing Date
2025-11-13
Accepted
2025-11-13 16:09:49
Documents
65
Period of Report
2025-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q trvi-20250930.htm   iXBRL 10-Q 2862874
2 EX-10.1 trvi-ex10_1.htm EX-10.1 67372
3 EX-31.1 trvi-ex31_1.htm EX-31.1 18073
4 EX-32.1 trvi-ex32_1.htm EX-32.1 12307
5 GRAPHIC img64809683_0.jpg GRAPHIC 40168
  Complete submission text file 0001193125-25-280166.txt   10455431

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT trvi-20250930.xsd EX-101.SCH 1160057
68 EXTRACTED XBRL INSTANCE DOCUMENT trvi-20250930_htm.xml XML 2004806
Mailing Address 195 CHURCH STREET 16TH FLOOR NEW HAVEN CT 06510
Business Address 195 CHURCH STREET 16TH FLOOR NEW HAVEN CT 06510 203-304-2499
Trevi Therapeutics, Inc. (Filer) CIK: 0001563880 (see all company filings)

EIN.: 450834299 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38886 | Film No.: 251478516
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)